Mycophenolate Mofetil
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Mycophenolate Mofetil |
| DrugBank ID | DB00688 |
| Brand Names (EU) | Myclausen |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.86% |
Approved Indication (EMA)
Myclausen is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | HIV infectious disease | 99.86% | DL |
| 2 | neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter | 99.76% | DL |
| 3 | bone Paget disease | 99.74% | DL |
| 4 | feline acquired immunodeficiency syndrome | 99.72% | DL |
| 5 | simian immunodeficiency virus infection | 99.72% | DL |
| 6 | multiple sclerosis | 99.54% | DL |
| 7 | hemosiderosis | 99.52% | DL |
| 8 | Heiner syndrome | 99.46% | DL |
| 9 | African iron overload | 99.36% | DL |
| 10 | neonatal hemochromatosis | 99.36% | DL |
| 11 | obsolete familial combined hyperlipidemia | 99.35% | DL |
| 12 | chronic hepatitis C virus infection | 99.32% | DL |
| 13 | hemosiderosis, pulmonary, with deficiency of gamma-a globulin | 99.32% | DL |
| 14 | hereditary hemochromatosis | 99.29% | DL |
| 15 | progressive relapsing multiple sclerosis | 99.28% | DL |
| 16 | AIDS | 99.25% | DL |
| 17 | gout | 99.16% | DL |
| 18 | skin disease | 98.89% | DL |
| 19 | psoriasis | 98.80% | DL |
| 20 | obsolete rare hereditary hemochromatosis | 98.79% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.